Last reviewed · How we verify
Cu-64 SARTATE and Cu-67 SARTATE
At a glance
| Generic name | Cu-64 SARTATE and Cu-67 SARTATE |
|---|---|
| Also known as | SARTATE, copper SARTATE, Cu-SARTATE, 64Cu-SARTATE, 67Cu-SARTATE |
| Sponsor | Clarity Pharmaceuticals Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma (PHASE1, PHASE2)
- Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cu-64 SARTATE and Cu-67 SARTATE CI brief — competitive landscape report
- Cu-64 SARTATE and Cu-67 SARTATE updates RSS · CI watch RSS
- Clarity Pharmaceuticals Ltd portfolio CI